<DOC>
	<DOCNO>NCT00167674</DOCNO>
	<brief_summary>Identifying new approach prevent breastmilk transmission HIV-1 important research priority . To end , clinical trial underway evaluate efficacy HAART ( zidovudine , lamivudine , nevirapine ) late pregnancy/lactation versus zidovudine/nevirapine peripartum prevention breastmilk HIV-1 transmission . It important understand mechanism effect antiretroviral ( ARV ) strategies prevention breastmilk HIV-1 transmission . This phase II trial compare HAART v peripartum zidovudine/nevirapine effect breastmilk HIV-1 , breastmilk HIV-1 specific immune response , infant HIV-1 specific immune response . 100 pregnant HIV-1 seropositive woman Nairobi CD4 count 200 500 chosen breastfeed receive either ARV regimen . Mother-infant pair follow 1 year delivery . Home visit conduct first month ( ~10 visit ) collect 2-5 ml breastmilk per visit . Mother-infant pair see study clinic maternal blood breastmilk infant blood collect month 1 , 3 , 6 HIV-1 HIV-1 Elispot assay . Breastmilk HIV-1 RNA DNA level quantify Dr. Overbaugh 's laboratory Seattle Elispot assay conduct Nairobi validation subset Dr. Rowland-Jones laboratory Oxford . Viral load , decay curve , half-life , re-population follow ARV cessation estimate regimen regimen compare . These study provide insight viral immune response ARV regimen propose prevention breastfeed HIV-1 transmission important rational design future intervention . After take account , estimate loss follow-up , target sample size outcome data 80 woman , 40 trial arm , estimate undetectable breast milk HIV-1 RNA level HAART arm median breast milk HIV-1 RNA level 3.0 log10 woman receive ZDV/NVP .</brief_summary>
	<brief_title>ARVs Prevent Breastmilk HIV : Viral Immune Responses</brief_title>
	<detailed_description>This randomize study compare breastfeed woman receive zidovudine/nevirapine ( 36 week delivery/first day postpartum ) woman receive HAART ( zidovudine , nevirapine , lamivudine ) initiate 36 week continue throughout lactation ( recommended 6 month , breastfeed cessation prior HAART cessation ) . This prospective cohort study follow HIV-1 seropositive woman infant conduct Nairobi . Women CD4 count 200 500 randomize one two regimen compare . The study procedure outline : 1 . Voluntary HIV-1 counseling test Nairobi City council antenatal clinic : collection blood use venipuncture follow write informed consent . 2 . Enrollment HIV-1 infect woman new cohort 32 wks gestation write informed consent 3 . Routine antenatal care include STD screen multivitamins/iron 4 . Collection maternal blood genital specimens 32 week STD diagnosis , HIV-1 RNA level , CD4 count , liver function test , complete blood count . 5 . Assignment treatment depend CD4 count 34 week : 1 . CD4 &gt; 500 zidovudine/nevirapine short-course treatment 2 . CD4 200-500 randomization zidovudine/nevirapine short-course 3-drugs ( nevirapine , zidovudine , 3TC ) pregnancy breastfeeding , recommendation stop breastfeed 6 month drug stop cessation breastfeed 3 . CD4 &lt; 200 3-drug regimen ( nevirapine , zidovudine , 3TC ) pregnancy breastfeed continued cessation breastfeed referral site Nairobi provide long-term treatment 6 . At delivery collection maternal breastmilk ( 2-5 ml ) , cord blood ( 15 ml ) , maternal blood ( 15 ml ) , infant blood ( 3 ml ) HIV-1 RNA , CD4 count , HIV-1 specific CTL assay , complete blood count , liver function test . 7 . Collection maternal breastmilk ( 2-5 ml ) home visit 3 time per week first 2 week , 2 time per week next two week . Filter paper blood specimen collect weekly home visit . 8 . Women receive 3-drug regimen expressible breastmilk cessation breastfeed cessation drug also home collection ( 3-5 ml ) specimens 3-times weekly 2 week cessation breastfeeding . 9 . Clinic visit week 2 , month 1 , 3 , 6 breastmilk blood collection . Higher volume breastmilk ( ~25 -50 ml ) collect clinic visit ( w2 , m1 , 3 , 6 ) HIV-1 RNA , DNA HIV-1 specific immune assay . Collection maternal blood week 2 , month 1 , 3 , 6 HIV-1 RNA level , CD4 count , HIV-1 CTL level , liver function test , complete blood count . 10 . Collection infant blood m1 , 3 , 6 HIV-1 HIV-1 specific immune response . Heel prick filter paper assay month 9 12 HIV-1 DNA PCR assay .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>The subject population recruit Mathare North Clinic Nairobi , Kenya voluntary HIV1 counsel test offer pregnant woman Pregnant woman test positive HIV1 antibody eligible study 18 year age At less 32 week ' gestation Have never previously expose antiretroviral medication Agree serial maternal blood Breast milk Infant blood draw Plan live Nairobi least year delivery . CD4 &gt; 500 &lt; 200 Not plan live Nairobi delivery Not plan breastfeed .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>breastmilk</keyword>
	<keyword>HIV-1</keyword>
	<keyword>antiretroviral</keyword>
	<keyword>mother-to-child</keyword>
	<keyword>transmission</keyword>
</DOC>